ENSCW (Ensysce Biosciences) Total Liabilities: $2.84 Mil (As of Mar. 2026)


ENSCW Ensysce Biosciences Inc ENSCW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is Ensysce Biosciences Total Liabilities?

Ensysce Biosciences ENSCW -9.20% 23 Total Liabilities is $2.84 Mil as of Mar. 2026. GuruFocus rates ENSCW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Ensysce Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 was $2.84 Mil.

Ensysce Biosciences's quarterly Total Liabilities increased from Sep. 2025 ($2.31 Mil) to Dec. 2025 ($4.57 Mil) but then declined from Dec. 2025 ($4.57 Mil) to Mar. 2026 ($2.84 Mil).

Ensysce Biosciences's annual Total Liabilities declined from Dec. 2023 ($3.36 Mil) to Dec. 2024 ($2.22 Mil) but then increased from Dec. 2024 ($2.22 Mil) to Dec. 2025 ($4.57 Mil).

Ensysce Biosciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Ensysce Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ensysce Biosciences Total Liabilities Chart

Ensysce Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 24.58 9.92 3.36 2.22 4.57

Ensysce Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.89 2.51 2.31 4.57 2.84
ENSCW
23GF Score
Ensysce Biosciences Inc ENSCW
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ensysce Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ensysce Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.568+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.57

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=7.452-2.885
=4.57

Ensysce Biosciences's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.837+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.84

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2.168--0.669
=2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.84 Mil mean?
Ensysce Biosciences (ENSCW) has a Total Liabilities of $2.84 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ensysce Biosciences and its competitors.
Is Ensysce Biosciences' Total Liabilities too high?
Ensysce Biosciences' current Total Liabilities is $2.84 Mil. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' Total Liabilities compare to PPCB and ACUT?
Ensysce Biosciences' Total Liabilities of $2.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ensysce Biosciences and its competitors. Ensysce Biosciences's current Total Liabilities is $2.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSCW) has a current Total Liabilities of $2.84 Mil. The current Total Liabilities is $2.84 Mil. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ensysce Biosciences (ENSCW), the current Total Liabilities is $2.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ensysce Biosciences Business Description

Other Exchanges ENSC:USA
Address 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score

Get the complete analysis for ENSCW

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price